Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
Holding ZYME?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.2Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: 1.31%
|Next Earnings Date:Aug 01, 2018
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with significant advancements in clinical and preclinical developments, strategic partnerships, and financial management, but also highlighted challenges such as decreased revenue and cash reserves, and a substantial impairment charge.Company Guidance
During Zymeworks' Q3 2024 earnings call, significant guidance was provided on various metrics and developments. Revenue for the nine months ended September 30, 2024, was reported at $45.3 million, down from $59.1 million in 2023, with notable contributions from Jazz Pharmaceuticals and BeiGene. A strategic share repurchase program of $60 million was discussed, with $30 million already completed, retiring 2.5 million shares at an average price of $11.79. The company's net loss reduced to $99.2 million compared to $104.2 million the previous year, attributed to decreased R&D and administrative expenses. Zymeworks maintains a strong cash position of $374.9 million, providing a financial runway into the second half of 2027. Clinical advancements include FDA clearance for ZW171 and ZW191, with ongoing Phase I trials and a focus on optimizing dosing strategies. Upcoming milestones include an R&D Day in December and a PDUFA date for zanidatamab on November 29, 2024.FDA Clearance for IND Applications
Zymeworks received FDA clearance for IND applications for ZW171 and ZW191 in August 2024, marking significant progress in their clinical development pipeline.
Promising Preclinical Data
Preclinical data for ZW220 and ZW251 presented at the ENA conference highlighted their potential, with ZW220 showing strong activity in various cancer models and ZW251 demonstrating efficacy in hepatocellular carcinoma models.
Research Milestone with GSK
Zymeworks recognized a $2.5 million research milestone from GSK, validating the strength of their platforms and technologies.
Strong Cash Position
Zymeworks reported $374.9 million in cash resources as of September 30, 2024, providing an expected cash runway into the second half of 2027.
Stock Repurchase Program
Completed the first $30 million of a $60 million stock repurchase program, buying approximately 2.5 million shares at an average price of $11.79 per share.
Net Loss Reduction
Net loss for the nine months ended September 30, 2024, was $99.2 million, down from $104.2 million in the same period in 2023, due to lower R&D and administrative expenses.
---
ZYME Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZYME Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $13.70 | $13.28 | -3.07% |
| Aug 01, 2024 | $10.11 | $10.20 | +0.89% |
| May 02, 2024 | $9.00 | $9.20 | +2.22% |
| Mar 06, 2024 | $12.23 | $11.44 | -6.46% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zymeworks Inc (ZYME) report earnings?
Zymeworks Inc (ZYME) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Zymeworks Inc (ZYME) earnings time?
Zymeworks Inc (ZYME) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZYME EPS forecast?
ZYME EPS forecast for the fiscal quarter 2024 (Q4) is -0.1.
---